ERBB2 and breast carcinoma: To test the efficacy and safety of the targeted delivery of Apt-HSA-CUR-NP to HER2-positive breast cancer cells, they used two cell lines, one HER2-positive (SK-BR3) and one HER2-negative (MCF-7).